Challenges in Enrolling Participants Halt Pfizer-BioNTech COVID Vaccine Trial

Pfizer and BioNTech have suspended their COVID-19 vaccine trial in adults aged 50 to 64 in the U.S. due to insufficient participant enrollment. The FDA's stringent requirements for placebo-controlled trials and difficulties in recruiting healthy participants without chronic conditions contributed to the decision. The trial aimed to collect efficacy, immune response, and safety data.

Pfizer and BioNTech recently announced the suspension of their large-scale COVID-19 vaccine trial in the United States for adults aged 50 to 64. This decision stems from the challenge of enrolling enough healthy participants to meet the trial's requirements, compounded by stricter demands set by the U.S. Food and Drug Administration (FDA).

The trial, which aimed to evaluate the efficacy, immune response, and safety of an updated vaccine formulation, required participants to be free from chronic conditions, a difficult criterion in this age group. The companies reported informing the FDA of the stoppage, citing difficulties in generating relevant post-marketing data due to slow enrollment.

While Pfizer and BioNTech's trial faced hurdles, Moderna continues a parallel study aiming for similar participant numbers, also encountering recruitment issues. The dwindling demand for COVID-19 boosters adds to the context, with only 18% of Americans receiving a booster during the 2025-26 season.

(With inputs from agencies.)